![]() |
UMIN-CTR Clinical Trial |
|
![]() |
![]() |
![]() |
![]() |
Name: | UMIN ID: |
Recruitment status | Preinitiation |
Unique ID issued by UMIN | UMIN000047976 |
Receipt No. | R000054428 |
Scientific Title | A study of improvement effects on salivary secretion by ingesting a food ingredient. |
Date of disclosure of the study information | 2022/06/22 |
Last modified on | 2022/06/27 |
Basic information | ||
Public title | A study of improvement effects on salivary secretion by ingesting a food ingredient. | |
Acronym | A study of improvement effects on salivary secretion by ingesting a food ingredient. | |
Scientific Title | A study of improvement effects on salivary secretion by ingesting a food ingredient. | |
Scientific Title:Acronym | A study of improvement effects on salivary secretion by ingesting a food ingredient. | |
Region |
|
Condition | ||
Condition | Healthy female adults | |
Classification by specialty |
|
|
Classification by malignancy | Others | |
Genomic information | NO |
Objectives | |
Narrative objectives1 | To confirm improvement effects on salivary secretion by ingesting a food ingredient for 8 weeks. |
Basic objectives2 | Safety,Efficacy |
Basic objectives -Others | |
Trial characteristics_1 | |
Trial characteristics_2 | |
Developmental phase |
Assessment | |
Primary outcomes | Salivary secretion |
Key secondary outcomes | 1. Comprehensive analysis of oral microbiome, and the number of oral bacteria
2. Salivary IgA, amylase, chromogranin A, cortisol, lactoferrin, lysozyme 3. Halitosis analysis 4. VAS 5. Short version of POMS2 6. OSA sleep inventory MA version 7. Pittsburg sleep questionnaire 8. NAD-metabolites in blood |
Base | |
Study type | Interventional |
Study design | |
Basic design | Parallel |
Randomization | Randomized |
Randomization unit | Individual |
Blinding | Double blind -all involved are blinded |
Control | Placebo |
Stratification | |
Dynamic allocation | |
Institution consideration | |
Blocking | |
Concealment |
Intervention | ||
No. of arms | 2 | |
Purpose of intervention | Treatment | |
Type of intervention |
|
|
Interventions/Control_1 | Ingestion of the test food without chewing, before or after breakfast, one tablet a day. | |
Interventions/Control_2 | Ingestion of the placebo food without chewing, before or after breakfast, one tablet a day. | |
Interventions/Control_3 | ||
Interventions/Control_4 | ||
Interventions/Control_5 | ||
Interventions/Control_6 | ||
Interventions/Control_7 | ||
Interventions/Control_8 | ||
Interventions/Control_9 | ||
Interventions/Control_10 |
Eligibility | ||||
Age-lower limit |
|
|||
Age-upper limit |
|
|||
Gender | Female | |||
Key inclusion criteria | (1) Female subjects aged 50 to 65 years old when consent acquisition.
(2) Postmenopausal subjects. (3) Subjects with resting salivary secretion of more than 1.5 g. (4) Subjects who can give informed consent to participate in this study, after being provided with an explanation of the protocol detail. |
|||
Key exclusion criteria | (1) Subjects who routinely use the health-specific/functional/supplementary/health foods which may affect this study (more than three times a week), and have any difficulty in stopping use after the consent.
(2) Subjects who have used medicines which may affect this study, more than two days a week, and have any difficulty in limiting use during this study. (3) Subjects who are planning to visit the hospital for cavity protection or oral cleaning during this study. (4) Subjects who have been determined as dry mouth symptom and/or Sjogren's syndrome. (5) Subjects with smoking habit, now and/or within a year before this study. (6) Subjects who drink a lot of alcohol. (7) Subjects having some kind of serious/progressive disease and symptom. (8) Subjects with previous/present medical history of serious diseases in heart, liver, kidney and digestive organs. (9) Subjects with some kind of drug and/or food allergy. (10) Subjects who are now under another clinical study with a medicine/food, or took part in that within 4 weeks before this study, or will join that after giving informed consent to join this study. (11) Subjects who donated over 200 mL of their whole blood and/or blood components within a month before this study. (12) Subjects who donated over 400 mL of their whole blood within the last 4 months before this study. (13) Subjects who will be collected over 800 mL in total of their blood within 12 months, before and in this study. (14) Subjects who have been determined as ineligible for participation, by the principal/sub investigator's opinions. |
|||
Target sample size | 60 |
Research contact person | |||||||
Name of lead principal investigator |
|
||||||
Organization | Meiji Holdings Co., Ltd. | ||||||
Division name | Group Leader | ||||||
Zip code | 192-0919 | ||||||
Address | 1-29-1 Nanakuni, Hachiouji, Tokyo192-0919, Japan | ||||||
TEL | 042-632-2680 | ||||||
masashi.morifuji@meiji.com |
Public contact | |||||||
Name of contact person |
|
||||||
Organization | CPCC Company Limited | ||||||
Division name | Clinical Planning Department | ||||||
Zip code | 103-0021 | ||||||
Address | 4F Daiwa Building, 3-3-10 Nihonbashi-Hongoku-Cho, Chuo-ku, Tokyo 103-0021, Japan | ||||||
TEL | 03-6225-9001 | ||||||
Homepage URL | |||||||
cpcc-contact@cpcc.co.jp |
Sponsor | |
Institute | CPCC Company Limited |
Institute | |
Department |
Funding Source | |
Organization | Meiji Holdings Co., Ltd. |
Organization | |
Division | |
Category of Funding Organization | Profit organization |
Nationality of Funding Organization |
Other related organizations | |
Co-sponsor | Chiyoda Oralhealth Care Clinic |
Name of secondary funder(s) |
IRB Contact (For public release) | |
Organization | Institutional Review Board of Chiyoda Paramedical Care Clinic |
Address | 2F Daiwa Building, 3-3-10 Nihonbashi-Hongoku-Cho, Chuo-ku, Tokyo 103-0021, Japan |
Tel | 03-6225-9005 |
IRB@cpcc.co.jp |
Secondary IDs | |
Secondary IDs | NO |
Study ID_1 | |
Org. issuing International ID_1 | |
Study ID_2 | |
Org. issuing International ID_2 | |
IND to MHLW |
Institutions | |
Institutions |
Other administrative information | |||||||
Date of disclosure of the study information |
|
Related information | |
URL releasing protocol | |
Publication of results | Unpublished |
Result | |
URL related to results and publications | |
Number of participants that the trial has enrolled | |
Results | |
Results date posted | |
Results Delayed | |
Results Delay Reason | |
Date of the first journal publication of results | |
Baseline Characteristics | |
Participant flow | |
Adverse events | |
Outcome measures | |
Plan to share IPD | |
IPD sharing Plan description |
Progress | |||||||
Recruitment status | Preinitiation | ||||||
Date of protocol fixation |
|
||||||
Date of IRB |
|
||||||
Anticipated trial start date |
|
||||||
Last follow-up date |
|
||||||
Date of closure to data entry | |||||||
Date trial data considered complete | |||||||
Date analysis concluded |
Other | |
Other related information |
Management information | |||||||
Registered date |
|
||||||
Last modified on |
|
Link to view the page | |
URL(English) | https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000054428 |
Research Plan | |
Registered date | File name |
Research case data specifications | |
Registered date | File name |
Research case data | |
Registered date | File name |